FDA Approves Another Interchangeable Biosimilar Drug | McDonnell Boehnen Hulbert & Berghoff LLP

On October 15th, the Food and Drug Administration approved its second interchangeable biosimilar drug.  That drug is Cyltezo (adalimumab-adbm), produced by Boehringer Ingelheim, which...

Related Keywords

Abbvie Humira ,Janet Woodcock ,Boehringer Ingelheim ,Drug Administration ,Biological Price Competition ,Innovation Act ,Affordable Care Act ,